Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI).
De Giglio A, Mezquita L, Auclin E, Blanc-Durand F, Riudavets M, Caramella C, Martinez G, Benitez JC, Martín-Romano P, El-Amarti L, Hendriks L, Ferrara R, Naltet C, Lavaud P, Gazzah A, Adam J, Planchard D, Chaput N, Besse B. De Giglio A, et al. Among authors: naltet c. Cancers (Basel). 2020 Sep 30;12(10):2827. doi: 10.3390/cancers12102827. Cancers (Basel). 2020. PMID: 33007977 Free PMC article.
Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer.
Geraud A, Mezquita L, Auclin E, Combarel D, Delahousse J, Gougis P, Massard C, Jovelet C, Caramella C, Adam J, Naltet C, Lavaud P, Gazzah A, Lacroix L, Rouleau E, Vasseur D, Mir O, Planchard D, Paci A, Besse B. Geraud A, et al. Among authors: naltet c. Cancers (Basel). 2020 Dec 14;12(12):3758. doi: 10.3390/cancers12123758. Cancers (Basel). 2020. PMID: 33327482 Free PMC article.
Grade 3-4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational Study.
Guezour N, Soussi G, Brosseau S, Abbar B, Naltet C, Vauchier C, Poté N, Hachon L, Namour C, Khalil A, Trédaniel J, Zalcman G, Gounant V. Guezour N, et al. Among authors: naltet c. Cancers (Basel). 2022 Aug 11;14(16):3878. doi: 10.3390/cancers14163878. Cancers (Basel). 2022. PMID: 36010872 Free PMC article.
Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.
Falchero L, Guisier F, Darrason M, Boyer A, Dayen C, Cousin S, Merle P, Lamy R, Madroszyk A, Otto J, Tomasini P, Assoun S, Canellas A, Gervais R, Hureaux J, Le Treut J, Leleu O, Naltet C, Tiercin M, Van Hulst S, Missy P, Morin F, Westeel V, Girard N. Falchero L, et al. Among authors: naltet c. Lung Cancer. 2023 Nov;185:107379. doi: 10.1016/j.lungcan.2023.107379. Epub 2023 Sep 22. Lung Cancer. 2023. PMID: 37757576 Free article.
[Role of immunotherapy in locally advanced non-small cell lung cancer].
Levy A, Doyen J, Botticella A, Bourdais R, Achkar S, Giraud P, Du C, Naltet C, Lavaud P, Besse B, Pradère P, Mercier O, Caramella C, Planchard D, Deutsch E, Le Péchoux C. Levy A, et al. Among authors: naltet c. Cancer Radiother. 2020 Feb;24(1):67-72. doi: 10.1016/j.canrad.2019.09.007. Epub 2020 Feb 6. Cancer Radiother. 2020. PMID: 32037126 French.
35 results